Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Omega-3 fatty acids may slow down early Alzheimer’s in some cases

10.10.2006
Omega-3 fatty acid supplements may slow cognitive decline in some patients with very mild Alzheimer’s disease, according to new findings from Karolinska Institutet (KI) in Sweden.

However, the positive affect of Omega-3 do not appear in cases with more advanced Alzheimer’s. This is the first clinical trial ever made in the field and the result is published in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

Alzheimer’s disease is a severely debilitating condition that affects thinking, learning and memory, beginning with declines in episodic memory. Medications are available to treat the symptoms, but these drugs do not affect the underlying cause and progression of the disease. Several studies have shown that eating fish, which is high in omega-3 fatty acids, may protect against Alzheimer’s disease, leading researchers to question whether supplements could have similar effects.

Dr Yvonne Freund-Levi and colleagues at KI in Stockholm and Uppsala University in Uppsala, Sweden, compared the effects of supplements containing two omega-3 fatty acids with placebo in 204 patients with Alzheimer’s disease, by which 174 completed the entire study. For six months, 89 patients (51 women and 38 men) took 1.7 grams of docosahexaenoic acid (DHA) and .6 grams of eicosapentaenoic acid (EPA), while 85 patients (39 women and 46 men) took placebo. For an additional six months, both groups took the omega-3 fatty acids. Patients had physical examinations, which included blood tests and blood pressure measurement, and took cognitive tests at the beginning of the study and at the six- and 12-month marks.

After six months, there was no difference in the rate of cognitive decline between the two groups. However, among a subgroup of 32 patients with very mild cognitive impairment at the beginning of the study, those who took the fatty acids experienced less decline in six months compared with those who took placebo. Among those who took placebo during the first six months, decline decreased during the second six months, when they also began taking the omega-3 supplements. The supplements appeared safe and well-tolerated, with no change in blood pressure or blood test results other than a higher ratio of fatty acids in the blood.

“These findings cannot serve as a basis for general recommendations for treatment of Alzheimer’s disease with dietary DHA-rich fish oil preparations”, says professor Jan Palmblad. “Studies in larger cohorts with mild cognitive impairment, including those at risk for Alzheimer’s disease, are needed to further explore the possibility that omega-3 fatty acids might be beneficial in halting initial progression of the disease.”

Publication: Omega-3 fatty acid treatment of 174 patients with mild to moderate Alzheimer’s disease (OmegAD): a randomized double-blind trial, Yvonne Freund Levi, Maria Eriksdotter-Jönhagen, Tommy Cederholm, Hans Basun, Gerd Faxén Irving, Anita Garlind, Inger Vedin, Bengt Vessby, Lars-Olof Wahlund, Jan Palmblad, Archives of Neurology, October 2006, ref. 2006; 63:1402-1408.

For further information, please contact:

Professor Tommy Cederholm, Department of Public Care and Caring Sciences/Clinical Nutrition and Metabolism, Uppsala University
Phone: +46-70-2733192
Email: Tommy.Cederholm@pubcare.uu.se
Professor Lars-Olof Wahlund, Department of Neurobiology, Caring Sciences and Society, Huddinge, KI.
Phone +46-70-7892045
E-mail: Lars-Olof.Wahlund@ki.se
Professor Jan Palmblad, Deparment of Medicine, Huddinge, KI
Phone: +46-8-585 826 93
Email: Jan.Palmblad@ki.se
Dr Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society, Huddinge, KI.
Phone +46-70-7892045
E-mail: Yvonne.Freund-Levi@ki.se
KI Press Officer:
Katarina Sternudd
Phone: +46-8-524 838 95
Email: katarina.sternudd@ki.se

Katarina Sternudd | alfa
Further information:
http://ki.se

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>